Vaccine catalog | Trial Phase | Enrolled patients backgrounds | Trial information | ||||||
---|---|---|---|---|---|---|---|---|---|
I | II | III | Number. | Location | intervention | comments | Identifier | Reference | |
Allogeneic | Â | Â | 18 | Sweden | allogeneic dendritic cell vaccine (ilixadencel) | Safety; immunological response activated against HCC | NCT01974661 | [20] | |
Autologous | I/IIa |  | 8/12 | China | autologous fixed HCC vaccine | Safety; recurrence delay for patients with HCC after operation | – | [21] | |
 |  |  | 41 | China | autologous fixed HCC vaccine | Safety; recurrence rates reduced and overall survival rates improved for patients with HCC after operation | – | [22] | |
 |  |  | 8 | USA | bi-shRNAfurin/GM-CSF incorporated autologous HCC cell vaccine | Safety; immunological response activated against HCC and overall survival prolonged | – | [23] | |
 | - |  |  | 160 | China | autologous DC-tumor vaccine | Safety; recurrence and metastasis rates for postoperative HCC patients reduced; survival rates improved | – | [24] |
 |  |  | 10 | Japan | autologous tumor lysates pulsed DC vaccine | Safety; antitumor efficiency probably existed against PLC: delayed type hypersensitivity induced (7/10); tumor size shrinked (1/10); serum level of tumor marker decreased (2/10) | – | [25] | |
 |  |  | 31 | China | autologous tumor lysates pulsed DC vaccine | Safety; HCC patients’ survival better prolonged by boosters followed DCs therapy than single DCs vaccine itself | – | [26] | |
 |  |  | 36 | Japan | autologous tumor lysates pulsed DC vaccine | Survival for iCCA patients prolonged; prognosis improved | UMIN000005820 | [27] |